April 19, 2018
A Virginia federal judge signed off Wednesday on Pfizer's $94 million settlement, including nearly $31 million in legal fees, with drug buyers who said the pharmaceutical giant extended its monopoly over the anti-inflammatory Celebrex by illegally blocking generic competition.
January 09, 2018
Hagens Berman Sobol Shapiro LLP, Berger & Montague PC and a handful of other firms on Monday asked a Virginia federal court to grant them about $31 million in fees after reaching a $94 million settlement with Pfizer Inc. over allegations that the company blocked competition for its anti-inflammatory drug Celebrex.
November 27, 2017
Pfizer and a class of direct purchasers who allege the drugmaker used fraudulent patents to delay generic competition for its anti-inflammatory drug Celebrex have told a Virginia federal court that they have reached a $94 million settlement agreement.
June 28, 2017
Pfizer and a proposed class of direct purchasers who allege the drugmaker used fraudulent patents to delay generic-drug competition for its Celebrex painkiller filed dueling motions for summary judgment in Virginia federal court Tuesday about whether Pfizer was wrongly reissued an invalid patent.
May 25, 2017
Pfizer asked a Virginia federal judge Wednesday to exclude expert testimony supporting the certification of a class of direct purchasers who allege the drugmaker used fraudulent patents to delay generic-drug competition for its Celebrex painkiller, saying the testimony is not reliable.
April 06, 2017
Purchasers of popular painkiller Celebrex on Wednesday asked a Virginia federal court to certify as a class action its suit against Pfizer accusing the drug giant of using fraudulent patents to delay generic-drug competition and maintain supracompetitive prices for the drug.